



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/07, 31/20	A1	(11) International Publication Number: WO 96/24344 (43) International Publication Date: 15 August 1996 (15.08.96)
(21) International Application Number: PCT/US95/16305 (22) International Filing Date: 8 December 1995 (08.12.95) (30) Priority Data: 08/388,043 10 February 1995 (10.02.95) US (71) Applicant: WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors: LEE, Helen, Tsenwhei; 3625 Fox Hunt, Ann Arbor, MI 48105 (US). PICARD, Joseph, Armand; 44809 Saltz Road, Canton, MI 48187 (US). RAMHARACK, Randy, Ranjee; 2465 Antietam Drive, Ann Arbor, MI 48105 (US). ROTH, Bruce, David; 6089 White Swan Lane, Ann Arbor, MI 48108 (US). SLISKOVIC, Drago, Robert; 3679 Hedgerow Drive, Saline, MI 48176 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) (57) Abstract Retinoids are effective to lower plasma levels of Lp(a) in mammals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

USE OF RETINIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a)

FIELD OF THE INVENTION

5

This invention relates to a method for lowering plasma levels of a lipoprotein known as lipoprotein(a), Lp(a), in animals comprising administering a retinoid compound.

10

BACKGROUND OF THE INVENTION

15

Heart disease remains one of the leading causes of death. The high incidence of heart disease has led to the identification of various risk factors that may be controlled in an effort to reduce such disease. One risk factor is hypercholesterolemia, which is a condition of high blood levels of cholesterol.

20

Cholesterol is a fatty substance that is made by the liver, and also is present in many foods. Cholesterol circulates in the blood associated with several forms of lipoproteins. Some of these forms are now referred to as "good" forms of cholesterol, while others are

25

"bad". For example, one such lipoprotein with which cholesterol associates is referred to as low-density lipoprotein or LDL. LDL-cholesterol (LDL-C) is the form in which cholesterol leaves the liver destined for cells throughout the body. High levels of LDL-C are

30

bad, because they have been shown to cause rapid clogging of coronary arteries with fatty deposits, resulting in the disease known as atherosclerosis, which often leads to heart attacks. A great deal of effort is currently underway to get people to reduce

35

their levels of LDL-C, for example, by modifying diet and exercise.

-2-

In contrast, a good form of cholesterol is that associated with high-density lipoprotein, ie, HDL-cholesterol (HDL-C). This is the form in which cholesterol is pulled out of cells and goes back to the liver for disposal.

A modified form of LDL is known as lipoprotein(a), "Lp(a)". It consists of LDL covalently linked through a disulfide bond to apolipoprotein(a), "apo(a)". Lp(a) cholesterol appears to be a bad form of cholesterol, since elevated levels of Lp(a) have been associated with the development of atherosclerosis, coronary heart disease, myocardial infarction, cerebral infarction, and restenosis following balloon angioplasty. In fact, Lp(a) appears to be an excellent predictor for stroke. Accordingly, high concentrations of Lp(a) is one of the major risk factors leading to death from heart disease.

We have now discovered that retinoids are effective in lowering plasma concentrations of Lp(a). This invention thus provides a method for lowering plasma levels of Lp(a) comprising administering a retinoid.

Retinoids are a class of natural and synthetic organic molecules which modulate the activity of retinoid responsive genes, mRNAs, and proteins. Some activities of retinoids occur by interaction with families of nuclear receptors, including the retinoic acid receptors and the retinoid X receptors. Vitamin A is a natural retinoid known as retinol. "Vitamin A acid" is retinoic acid. Retinoids have been reported to have a number of biological activities. For example, they are said to be potent agents for control of both cellular differentiation and proliferation. They have been reported to moderate the growth of tumors and to affect the immune system, see Gale, Progress in Medicinal Chem. 1993;30, Ellis and Luscombe ed., Elsevier Publishers.

- 3 -

Retinoids have also been reported to have effects on plasma concentrations of lipoproteins. For example, Lyons, et al., Br. J. Dermatology 1982;107:591-5, reported a decrease in HDL-C levels in patients given
5 13-cis-retinoic acid. Ringer, et al., Am. J. Chem. Nutr. 1991;53:688-94, reported an increase in HDL concentrations in patients given β -carotene, but did not find any changes in apolipoprotein A or B levels. Katocs, et al., US Patent 5,219,888, reported that
10 retinoids increase plasma HDL levels.

There have been no reports that retinoids effect plasma levels of Lp(a). We have now discovered that plasma Lp(a) can be lowered by administering retinoids, and accordingly an object of this invention is to
15 provide a method for lowering Lp(a), and thereby treating and preventing coronary artery disease.

SUMMARY OF THE INVENTION

This invention provides a method for lowering plasma levels of Lp(a) using a retinoid. More particularly, the invention is a method for lowering plasma levels of Lp(a) in animals comprising
20 administering to an animal an Lp(a) lowering amount of a retinoid. By lowering Lp(a) levels, the animals are protected against developing premature atherosclerosis and consequent coronary artery disease.


Numerous compounds are known which are
30 characterized as retinoids. A comprehensive discussion of retinoids is given by Dawson and Hobbs, in Chapter 2 of The Retinoids: Biology, Chemistry, and Medicine, 2nd ed., Sporn, Roberts, and Goodman, Raven Press, Ltd., New York, 1994. That reference is incorporated
35 herein by reference for its teaching of the synthesis of retinoids. All that is required by this invention

- 4 -

is that a compound characterized as a retinoid is administered to an animal in an Lp(a) lowering amount.

Preferred retinoids to be utilized in the present invention include retinoic acid of the formula


5



10

Retinoic acid derivatives also are preferred, for example compounds of the formula

15




wherein Ar is an aryl group and "ester" is an organic ester forming group.

20

Retinoids which are dienyl benzoic acid and enzynylaryl carboxylic acids also are preferred. For example, compounds of the formula

25




where R_1 is cycloalkyl or aryl, and R_2 is a typical phenyl substituted group such as halo, alkyl, alkoxy, alkylthio, and the like.

30


Compounds such as

35



- 5 -

where R_3 is, for instance



also are preferred.

All of the retinoids required for this invention are known and available by well-known synthetic methodologies.


10 A further embodiment of this invention is a method for identifying animals who are likely to encounter a stroke. Such animals have a higher than normal plasma level of Lp(a). The method comprising determining plasma level of Lp(a) and comparing it to levels that
15 are normal for the particular age and sex group to which the subject belongs.

20 DETAILED DESCRIPTION OF THE INVENTION

All that is required for this invention is to administer an Lp(a) lowering amount of a retinoid to an animal in order to diminish plasma levels of Lp(a).

25 Preferred retinoids to be utilized are benzoic acids and carboxylic acids and esters thereof, particularly C_1 - C_6 alkyl esters, such as methyl, ethyl, isopropyl, isopentyl, and n-hexyl.

Typical benzoic acids to be utilized include those of the formula




35 wherein R_1 is cycloalkyl or aryl and R_2' independently are:


-6-

R_2 substituent group such as halo, hydroxy, amine, mono- and dialkyl amino, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, or C_1 - C_6 alkylthio, and n is 0 or 1. The cycloalkyl group can be a single ring, for instance a C_3 - C_7 cycloalkyl ring, optionally substituted with halo, alkyl, alkoxy, alkylthio, or the like, or bicyclic. Similarly, the aryl can be monocyclic or bicyclic, for instance, phenyl or naphthyl, it can be cycloalkyl fused to an aromatic ring, for instance, a benzocyclohexane or benzocycloheptane, and any of the ring systems can contain heteroatoms, for instance, 1, 2, or 3 heteroatoms selected from sulfur, oxygen, and nitrogen. The rings can also be substituted, for example, with 1, 2, or 3 groups such as R_2 and R_2' . Many of the retinoids have an alkylene chain which can exist as cis and trans isomers. Both the all cis and all trans, as well as mixtures, can be used herein.


Examples of preferred retinoids to be utilized in the method of this invention include those having the following structures:





where R_1 is, for instance








and R_2 is hydrogen, halo, or alkoxy;



- 7 -

where R_1 is

where R_1 is alkyl or dialkylphenyl, or a bi- or tricyclic ring such as:



- 8 -

The typical specific retinoids which can be utilized in the method of the invention include the following:

- 5 4-[4-(4,4-Dimethyl-thiochroman-6-yl)-2-methyl-but-1,3-dienyl]-benzoic acid;
- 3-Fluoro-4-[2-methyl-4-(2,6,6-trimethyl-cyclohex-1-enyl)-but-1,3-dienyl]-benzoic acid;
- 3-Methoxy-4-[2-methyl-4-(2,6,6-trimethyl-cyclohex-1-enyl)-but-1,3-dienyl]-benzoic acid;
- 10 5-[4-(2,6,6-Trimethyl-cyclohex-1-enyl)-but-3-en-1-ynyl]-thiophene-2-carboxylic acid ethyl ester;
- 5-[4-(2,6,6-Trimethyl-cyclohex-1-enyl)-but-3-en-1-ynyl]-furan-2-carboxylic acid ethyl ester;
- 6-[4-(2,6,6-Trimethyl-cyclohex-1-enyl)-but-3-en-1-ynyl]-nicotinic acid;
- 15 4-[2-(3-tert-Butyl-phenyl)-propenyl]-benzoic acid;
- 4-[2-(4-tert-Butyl-phenyl)-propenyl]-benzoic acid;
- 4-[2-(3,4-Dimethyl-phenyl)-propenyl]-benzoic acid;
- 4-[2-(3,4-Diethyl-phenyl)-propenyl]-benzoic acid;
- 20 4-[2-(3,4-Diisopropyl-phenyl)-propenyl]-benzoic acid;
- 4-[2-(5-Isobutyl-tricyclo[6.2.1.0^{2,7}]-undeca-2,4,6-trien-4-yl)-propenyl]-benzoic acid;
- 4-[2-(3,6-Dimethoxy-tricyclo[6.2.1.0^{2,7}]-undeca-2,4,6-trien-4-yl)-propenyl]-benzoic acid;
- 25 Benzoic acid, 4-[2-(2,3,4,4a-tetrahydro-4a,10,10-trimethyl-1H-3,9b-methanodibenzofuran-8-yl)ethenyl]-;
- 4-[2-(6,7,8,9-Tetrahydro-5H-benzocyclohepten-2-yl)propenyl]-benzoic acid;
- 30 4-[2-(7-Methyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;
- 4-[2-(5,5-Dimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;
- 35

-9-

4- [2- (3,7,7-Trimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid methyl ester;

5 4- [2- (7,7-Dimethyl-3-octyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid;

4- [2- (7-Ethyl-7-methyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

10 Benzoic acid, 4- [2- (5,6,8,9-tetrahydro-spiro[7H-benzocycloheptene-7,1'-cyclopropane]-2-yl)-1-propenyl]-, ethyl ester;

Benzoic acid, 4- [2- (5,6,8,9-tetrahydro-spiro[7H-benzocycloheptene-7,1'-cyclopentane]-2-yl)-1-propenyl]-, ethyl ester;

15 4- [2- (7-Oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

4- [2- (9-Methyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

20 4- [2- (5,5,9-Trimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

4- [2- (7,7,9-Trimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

4- [2- (5,9,9-Trimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

25 4- [2- (7,7,9,9-Tetramethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid;

4- [2- (6,6,8,8-Tetramethyl-7-oxo-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yl)-propenyl]-benzoic acid ethyl ester;

30 4- [2- (4,4-Dimethyl-chroman-7-yl)-propenyl]-benzoic acid;

4- [2- (4,4-Dimethyl-1,1-dioxo-thiochroman-7-yl)-propenyl]-benzoic acid;

35 4- [2- (1,4,4-Trimethyl-1,2,3,4-tetrahydro-quinolin-7-yl)-propenyl]-benzoic acid;

-10-

- 4- [2- (2,3-Dihydro-benzo[1,4]dioxin-6-yl) -
propenyl] -benzoic acid;
- 4- [2- (2,3-Dihydro-benzo[1,4]dithiin-6-yl) -
propenyl] -benzoic acid;
- 5 4- [2- (1,4-Dimethyl-1,2,3,4-tetrahydro-quinoxalin-
6-yl) -propenyl] -benzoic acid;
- 4- [2- (2,3,4,5-Tetrahydro-benzo[b]oxepin-8-yl) -
propenyl] -benzoic acid;
- 4- [2- (2,3,4,5-Tetrahydro-benzo[b]oxepin-7-yl) -
10 propenyl] -benzoic acid;
- 4- [2- (2,3,4,5-Tetrahydro-benzo[b]thiepin-8-yl) -
propenyl] -benzoic acid;
- 4- [2- (5-Methyl-2,3,4,5-tetrahydro-benzo[b]thiepin-
8-yl) -propenyl] -benzoic acid;
- 15 4- [2- (5,5-Dimethyl-2,3,4,5-tetrahydro-
benzo[b]thiepin-8-yl) -propenyl] -benzoic acid;
- 4- [2- (3,3-Dimethyl-2,3,4,5-tetrahydro-
benzo[b]thiepin-8-yl) -propenyl] -benzoic acid;
- 4- [2- (2,3,4,5-Tetrahydro-benzo[b]thiepin-7-yl) -
20 propenyl] -benzoic acid;
- 4- [2- (5-Methyl-2,3,4,5-tetrahydro-benzo[b]thiepin-
7-yl) -propenyl] -benzoic acid;
- 4- [2- (3-Methyl-2,3,4,5-tetrahydro-benzo[b]thiepin-
7-yl) -propenyl] -benzoic acid;
- 25 4- [2- (3,5,5-Trimethyl-2,3,4,5-tetrahydro-
benzo[b]thiepin-7-yl) -propenyl] -benzoic acid;
- 4- [2- (3,3-Dimethyl-2,3,4,5-tetrahydro-
benzo[b]thiepin-7-yl) -propenyl] -benzoic acid;
- 4- [2- (1,1-Dioxo-2,3,4,5-tetrahydro-
30 benzo[b]thiepin-8-yl) -propenyl] -benzoic acid;
- 4- [2- (1,1-Dioxo-2,3,4,5-tetrahydro-
benzo[b]thiepin-7-yl) -propenyl] -benzoic acid;
- 4- [2- (5,5-Dimethyl-1,1-dioxo-2,3,4,5-tetrahydro-
benzo[b]thiepin-7-yl) -propenyl] -benzoic acid;
- 35 4- [2- (3-Methyl-1,1-dioxo-2,3,4,5-tetrahydro-
benzo[b]thiepin-7-yl) -propenyl] -benzoic acid;

-11-

4 - [2 - (3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl) -
propenyl] - benzoic acid;

4 - [2 - (3-Methyl-3,4-dihydro-2H-benzo[b][1,4] -
dioxepin-7-yl) - propenyl] - benzoic acid;

5 4 - [2 - (7,7-Dimethyl-7,8-dihydro-6H-5-oxa-9-thia-
benzocyclohepten-2-yl) - propenyl] - benzoic acid;

4 - [2 - (7,8-Dihydro-6H-5,9-dithia-benzocyclohepten-
2-yl) - propenyl] - benzoic acid;

10 4 - [2 - (7-Methyl-7,8-dihydro-6H-5,9-dithia-
benzocyclohepten-2-yl) - propenyl] - benzoic acid;

4 - [2 - (5-Methyl-2,3,4,5-tetrahydro-
benzo[b][1,4]thiazepin-8-yl) - propenyl] - benzoic acid;

4 - [2 - (3,5-Dimethyl-2,3,4,5-tetrahydro-
benzo[b][1,4]thiazepin-8-yl) - propenyl] - benzoic acid;

15 4 - [2 - (2,2-Dimethyl-benzo[1,3]dioxol-5-yl) -
propenyl] - benzoic acid;

4 - [2 - (2,2-Dimethyl-benzo[1,3]dithiol-5-yl) -
propenyl] - benzoic acid;

4-Styryl-benzoic acid;

20 4 - [2 - (4-tert-Butyl-phenyl) - vinyl] - benzoic acid;

4 - (2-Tricyclo[6.2.1.0>2,7_]undeca-2,4,6-trien-
4-yl-vinyl) - benzoic acid;

25 Benzoic acid, 4 - [2 - (2,3,4,4a-tetrahydro-
4a,10,10-trimethyl-1H-3,9b-methanodibenzofuran-8-yl) -
ethenyl] - ;

4 - [2 - (4-Methoxy-2,3,6-trimethyl-phenyl) - vinyl] -
benzoic acid;

4 - {2 - [4 - (3-Methyl-but-2-enyloxy) - phenyl] - vinyl} -
benzoic acid ethyl ester;

30 4 - {2 - [2-Methyl-4 - (3-methyl-but-2-enyloxy) - phenyl] -
vinyl} - benzoic acid ethyl ester;

4 - {2 - [2-Methyl-4 - (3-methyl-but-2-enylsulfanyl) -
phenyl] - vinyl} - benzoic acid ethyl ester;

35 4 - [2 - (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl) - vinyl] - benzoic acid;

- 12 -

- 4- [2- (1-Methoxy-4,5,5,8,8-pentamethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 5 4- [2- (1-Methoxy-3,5,5,8,8-pentamethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 10 4- [2- (1,4-Dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 15 4- [2- (1,3-Dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 4- [2- (1-Ethoxy-3-methoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 4- [2- (1-Isopropoxy-3-methoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 20 4- [2- (3-Methoxy-5,5,8,8-tetramethyl-1-propoxy-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 4- [2- (1-Butoxy-3-methoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 25 4- [2- (1-Hexyloxy-3-methoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzoic
acid;
- 4- (1,1,3,3-Tetramethyl-indan-5-ylethynyl) -benzoic
acid;
- 30 4- (1,1,2,3,3-Pentamethyl-indan-5-ylethynyl) -
benzoic acid;
- 4- (3,8,8-Trimethyl-5,6,7,8-tetrahydro-naphthalen-
2-ylethynyl) -benzoic acid;
- 35 4- (3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-ylethynyl) -benzoic acid;

-13-

6- (4,4,7-Trimethyl-chroman-6-ylethynyl) -nicotinic acid ethyl ester;

6- (3,3,4,4-Tetramethyl-chroman-6-ylethynyl) -nicotinic acid ethyl ester;

5 6- (3,3,4,4,7-Pentamethyl-chroman-6-ylethynyl) -nicotinic acid ethyl ester;

6- (4,4-Dimethyl-thiochroman-6-ylethynyl) -nicotinic acid ethyl ester;

10 6- (4,4,7-Trimethyl-thiochroman-6-ylethynyl) -nicotinic acid ethyl ester;

4- [5- (1,1,2,3,3-Pentamethyl-indan-5-yl) -1H-pyrazol-3-yl] -benzoic acid methyl ester;

4- [5- (3-Methyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -1H-pyrazol-3-yl] -benzoic acid methyl ester;

15 4- [3- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -pyrazol-1-yl] -benzoic acid;

4- [2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -1H-imidazol-4-yl] -benzoic acid ethyl ester;

20 4- [5- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -1H-imidazol-2-yl] -benzoic acid methyl ester;

25 4- [5-Oxo-3- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -4,5-dihydro-pyrazol-1-yl] -benzoic acid;

4- [2-Mercapto-4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -imidazol-1-yl] -benzoic acid;

30 4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -oxazol-2-yl] -benzoic acid methyl ester;

4- [5- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -oxazol-2-yl] -benzoic acid methyl ester;

- 14 -

4- [5- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -oxazolidin-3-yl] -benzoic acid ethyl ester;

5 4- [3- (7-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -isoxazol-5-yl] -benzoic acid;

4- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -thiazol-2-yl] -benzoic acid methyl ester;

10 4- [3- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) - [1,2,4]oxadiazol-5-yl] -benzoic acid methyl ester;

4- [6- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -pyridazin-4-yl] -benzoic acid methyl ester;

15 4- [6- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -pyridazin-3-yl] -benzoic acid methyl ester;

20 4- [2-Hydroxy-6- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -pyrimidin-4-yl] -benzoic acid butyl ester;

6-m-Tolyl-naphthalene-2-carboxylic acid;

6- (3-tert-Butyl-phenyl) -naphthalene-2-carboxylic acid;

25 6- (3-tert-Butyl-4-methoxy-phenyl) -naphthalene-2-carboxylic acid;

6- (3-Adamantan-1-yl-4-methoxy-phenyl) -naphthalene-2-carboxylic acid;

30 6- (3-Adamantan-1-yl-4-hexyloxy-phenyl) -naphthalene-2-carboxylic acid;

6- (3-Adamantan-1-yl-4-decyloxy-phenyl) -naphthalene-2-carboxylic acid;

35 2-Naphthalenecarboxylic acid, 6- (2,3,4,4a-tetrahydro-4a,10,10-trimethyl-1H-3,9b-methanodibenzofuran-8-yl) -;

-15-

6- [4- (Methoxy-3- (1-methyl-1-nonyloxy-ethyl) -
phenyl)] -naphthalene-2-carboxylic acid;

6- (3,4-Dimethoxy-phenyl) -naphthalene-2-carboxylic
acid;

5 6- [4- (Adamantan-1-ylsulfanyl) -phenyl] -naphthalene-
2-carboxylic acid;

8-Methoxy-5',5',8',8'-tetramethyl-
5',6',7',8'-tetrahydro- [2,2']binaphthalenyl-
6-carboxylic acid;

10 6- (3-Adamantan-1-yl-4-methoxy-phenyl) -4-hydroxy-
1-methyl-naphthalene-2-carboxylic acid;

2- (4-tert-Butyl-phenyl) -benzofuran-6-carboxylic
acid;

15 2- (4-tert-Butyl-phenyl) -benzo [b] thiophene-
6-carboxylic acid;

2- (4-tert-Butyl-phenyl) -1H-indole-6-carboxylic
acid;

2- (3-tert-Butyl-4-methoxy-phenyl) -benzofuran-
6-carboxylic acid;

20 2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl) -benzofuran-6-carboxylic acid;

2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl) -benzooxazole-6-carboxylic acid;

25 2- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl) -3H-benzimidazole-5-carboxylic acid;

2- (3-Adamantan-1-yl-4-methoxy-phenyl) -benzofuran-
6-carboxylic acid;

2- (3-Adamantan-1-yl-4-methoxy-phenyl) -
benzo [b] thiophene-6-carboxylic acid;

30 2- (3-Adamantan-1-yl-4-methoxy-phenyl) -3H-benzo-
imidazole-5-carboxylic acid;

2- (3-Adamantan-1-yl-4-hydroxy-phenyl) -3H-benzo-
imidazole-5-carboxylic acid;

35 2- (3-Adamantan-1-yl-4-decyloxy-phenyl) -
benzooxazole-6-carboxylic acid;

-16-

Benzo[b]thiophene-6-carboxylic acid, 2-(2,3,4,4a-tetrahydro-4a,10,10-trimethyl-1H-3,9b-methanodibenzofuran-8-yl)-;

5 6-[Hydroxy-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-naphthalene-2-carboxylic acid;

6-[Acetoxy-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-methyl]-naphthalene-2-carboxylic acid;

10 6-(1,1,3,3-Tetramethyl-indane-5-carbonyl)-naphthalene-2-carboxylic acid;

6-[Hydroxy-(1,1,2,3,3-pentamethyl-indan-5-yl)-methyl]-naphthalene-2-carboxylic acid;

15 6-(6,7-Dimethyl-naphthalene-2-carbonyl)-naphthalene-2-carboxylic acid;

6-(6-Methoxy-naphthalene-2-carbonyl)-naphthalene-2-carboxylic acid;

6-(6-Methoxy-5,8-dimethyl-naphthalene-2-carbonyl)-naphthalene-2-carboxylic acid;

20 6-[Hydroxy-(6-methoxy-5,8-dimethyl-naphthalen-2-yl)-methyl]-naphthalene-2-carboxylic acid;

6-(6-Methoxy-5,8-dimethyl-naphthalen-2-ylmethyl)-naphthalene-2-carboxylic acid;

25 6-(4,4-Dimethyl-chroman-6-carbonyl)-naphthalene-2-carboxylic acid;

6-[(4,4-Dimethyl-chroman-6-yl)-hydroxy-methyl]-naphthalene-2-carboxylic acid;

6-(4,4-Dimethyl-chroman-6-ylmethyl)-naphthalene-2-carboxylic acid;

30 2-Naphthalenecarboxylic acid, 6-[(2,3,4,4a-tetrahydro-4a,10,10-trimethyl-1H-3,9b-methanodibenzofuran-8-yl)carbonyl]-;

6-(2,2-Dimethyl-chroman-6-carbonyl)-naphthalene-2-carboxylic acid;

35 6-(4-tert-Butyl-benzoyl)-naphthalene-2-carboxylic acid;

-17-

6-[(2,4-Di-tert-butyl-phenyl)-hydroxy-methyl]-
naphthalene-2-carboxylic acid;

6-(2,4-Diisopropyl-benzoyl)-naphthalene-
2-carboxylic acid;

5 6-(2,4-Diisopropyl-benzyl)-naphthalene-
2-carboxylic acid;

6-(4-Cyclohexyl-benzoyl)-naphthalene-2-carboxylic
acid;

10 6-(4-Phenoxy-benzoyl)-naphthalene-2-carboxylic
acid;

6-(4-Methoxy-benzoyl)-naphthalene-2-carboxylic
acid;

6-(6-Methoxy-biphenyl-3-carbonyl)-naphthalene-
2-carboxylic acid;

15 6-(3-Adamantan-1-yl-4-methoxy-benzoyl)-
naphthalene-2-carboxylic acid;

6-(4-Methoxy-2,3,6-trimethyl-benzoyl)-naphthalene-
2-carboxylic acid;

20 2-(1,1,3,3-Tetramethyl-indane-5-carbonyl)-benzoic
acid;

2-(1,1,2,3,3-Pentamethyl-indane-5-carbonyl)-
benzoic acid;

2-(3,6-Dimethoxy-tricyclo[6.2.1.0>2,7_]undeca-
2(7),3,5-triene-4-carbonyl)-benzoic acid;

25 2-(1,1,2,3,3-Pentamethyl-indane-5-carbonyl)-
cyclohex-1-enecarboxylic acid;

2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalene-2-carbonyl)-cyclohexanecarboxylic acid;

30 2-(1,1,2,3,3-Pentamethyl-indane-5-carbonyl)-
cyclohexanecarboxylic acid;

4-(Tricyclo[6.2.1.0>2,7_]undeca-2(7),3,5-triene-
4-carbonyl)-benzoic acid;

4-(1,1,2,3,3-Pentamethyl-indane-5-carbonyl)-
benzoic acid;

35 4-[Hydroxy-(5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-naphthalen-2-yl)-methyl]-benzoic acid;

-18-

- 4- (2,4-Diisopropyl-benzoyl) -benzoic acid;
- 4- [(2,4-Diisopropyl-phenyl) -hydroxy-methyl] -
benzoic acid;
- 4- (3,5-Di-tert-butyl-4-hydroxy-benzoyl) -benzoic
5 acid;
- 4- [Hydroxy- (6-methoxy-5,8-dimethyl-naphthalen-
2-yl) -methyl] -benzoic acid;
- 4- [(4,4-dimethyl-thiochroman-6-yl) -hydroxy-
methyl] -benzoic acid;
- 10 4- (3-Oxo-3-phenyl-propenyl) -benzoic acid;
- 4- [3- (3,4-Diethyl-phenyl) -3-oxo-propenyl] -benzoic
acid;
- 4- [3- (3,4-Diisopropyl-phenyl) -3-oxo-propenyl] -
benzoic acid;
- 15 4- [3- (4-tert-Butyl-phenyl) -3-oxo-propenyl] -benzoic
acid;
- 4- [3- (3-tert-Butyl-phenyl) -3-oxo-propenyl] -benzoic
acid;
- 4- [3- (3,5-Di-tert-butyl-phenyl) -3-oxo-propenyl] -
20 benzoic acid;
- 4- [3- (2,5-Di-tert-butyl-phenyl) -3-oxo-propenyl] -
benzoic acid;
- 4- [3-Oxo-3- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl) -propenyl] -benzoic acid;
- 25 4- [3-Oxo-3- (3,5,5,8,8-pentamethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl) -propenyl] -benzoic acid;
- 2-Hydroxy-4- [3-oxo-3- (5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -propenyl] -benzoic
acid;
- 30 4- [3- (4,4-Dimethyl-chroman-6-yl) -3-oxo-propenyl] -
benzoic acid;
- 4- [3- (4,4-Dimethyl-chroman-7-yl) -3-oxo-propenyl] -
benzoic acid;
- 4- [3- (4,4-Dimethyl-thiochroman-6-yl) -3-oxo-
35 propenyl] -benzoic acid;

- 19 -




4- [3- (3,4-Dimethoxy-phenyl) -3-oxo-propenyl] -
benzoic acid;

4- [1-Hydroxy-3- (2-hydroxy-phenyl) -3-oxo-propenyl] -
benzoic acid;

5 4- [3- (5-tert-Butyl-2-hydroxy-phenyl) -1-hydroxy-
3-oxo-propenyl] -benzoic acid; and

4- [3- (4-tert-butyl-2-hydroxy-phenyl) -1-hydroxy-
3-oxo-propenyl] -benzoic acid.


10 Other retinoids which can be utilized to lower
plasma levels of Lp(a) include polyolefinic carboxylic
acids, aldehydes, and alcohols having the general
formula



25 where R_1 includes the cycloalkyl and aryl groups such
as those described above, and n is 0 or 1.

Typical R_1 groups additionally include the
following: alkyl such as ethyl and hexyl; cycloalkyl
such as cyclohexyl, alkylcyclohexyl, dialkylcyclohexyl,
cyclohexenyl, cyclopentyl, dialkylcyclopentyl,
30 cyclopentenyl, mono- and dialkylcyclopentyl; and aryl
such as phenyl, hydroxyphenyl, methoxyphenyl,
halophenyl, thienyl, furanyl, pyridyl, and polycyclic
systems, such as

- 20 -



-21-

The retinoids to be utilized in this invention also include the various stereochemical isomers, for example, the all trans isomers (E,E,E,E), the 9-cis isomers (E,E,Z,E), and the 13-cis isomers (Z,E,E,E).

5 Typical retinoids of the above class which can be utilized to lower Lp(a) include the following:

3,7-Dimethyl-undeca-2,4,6,8-tetraenal;

9-Cyclohexyl-3,7-dimethyl-nona-2,4,6,8-tetraenal;

10 3,7-Dimethyl-9-(2,2,6-trimethyl-cyclohexyl)-nona-2,4,6,8-tetraenal;

9-Cyclohex-1-enyl-3,7-dimethyl-nona-2,4,6,8-tetraenal;

3,7-Dimethyl-9-(2-methyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

15 9-(6,6-Dimethyl-cyclohex-1-enyl)-3,7-dimethyl-nona-2,4,6,8-tetraenal;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

20 9-(2,6-Dimethyl-cyclohex-1-enyl)-3,7-dimethyl-nona-2,4,6,8-tetraenal;

3-Methyl-9-(2,5,5-trimethyl-cyclopent-1-enyl)-nona-2,4,6,8-tetraenal;

10-Isopropyl-3-methyl-dodeca-2,4,6,8,10-pentaenal;

3-Methyl-dodeca-2,4,6,8,10-pentaenal;

25 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohexa-1,3-dienyl)-nona-2,4,6,8-tetraenal;

3,7-Dimethyl-9-phenyl-nona-2,4,6,8-tetraenal;

9-(3-Hydroxy-2,6,6-trimethyl-cyclohex-1-enyl)-3,7-dimethyl-nona-2,4,6,8-tetraenal;

30 3,7-Dimethyl-9-(2,6,6-trimethyl-3-oxo-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

3,7-Dimethyl-9-(2,2,6-trimethyl-7-oxa-bicyclo[4.1.0]hept-1-yl)-nona-2,4,6,8-tetraenal;

35 3,7-Dimethyl-9-(2,2,6-trimethyl-7-oxa-bicyclo[4.1.0]hept-4-en-1-yl)-nona-2,4,6,8-tetraenal;

- 22 -

- 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenal;
- 3-Methyl-9-(2,4,5-trimethyl-thiophen-3-yl)-nona-2,4,6,8-tetraenal;
- 5 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)-nona-2,4,6,7-tetraen-1-ol;
- All trans-9-(4-Dimethylamino-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenal;
- 3,7,11-Trimethyl-dodeca-2,4,6,8,10-pentaenal;
- 10 3,7-Dimethyl-9-(2,2,6-trimethyl-cyclohexylidene)-nona-2,4,6,8-tetraenal;
- 3-Methyl-7-(4,4,7a-trimethyl-2,4,5,6,7,7a-hexahydro-benzofuran-3-yl)-octa-2,4,6-trienal;
- 9-(2,2-Dimethyl-6-methylene-cyclohexyl)-
- 15 3,7-dimethyl-nona-2,4,6,8-tetraenal;
- 9-Adamantan-2-ylidene-3,7-dimethyl-nona-2,4,6,8-tetraenal;
- 5,9-Dimethyl-11-(2,6,6-trimethyl-cyclohex-1-enyl)-undeca-2,4,6,8,10-pentaenal;
- 20 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,8-trienal;
- 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,8-dienal;
- 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
- 25 nona-2,4,6-trienal;
- 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,6,8-trien-1-ol;
- 2,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;
- 30 13-(2,6,6-Trimethyl-cyclohex-1-enyl)-trideca-2,4,6,8,10,12-hexaenal;
- 17-(2,6,6-Trimethyl-cyclohex-1-enyl)-heptadeca-2,4,6,8,10,12,14,16-octaenal;
- 7-Ethyl-3-methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;
- 35

-23-

2,3,7-Trimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

7-Methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

5 2,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraen-1-ol;

(E,E,E)-3,7-dimethyl-undeca-2,6,8-trien-4-yn-1-ol;

(Z,E,E)-3,7-dimethyl-undeca-2,6,8-trien-4-yn-1-ol;

10 (E,E,E)-2,2,7-trimethyl-3-methylene-undeca-4,6,8-trienoic acid;

(Z,E,E,E)-2,3,7-trimethyl-undeca-2,4,6,8-tetraenoic acid;

7-Methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

15 {5-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-cyclohept-3-enylidene}-acetaldehyde;

{4-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-cyclohept-2-enylidene}-acetaldehyde;

20 3-Bromo-7-methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

6-Fluoro-7-methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

7-Methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-4,6,8-trien-2-ynal;

25 6,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

3-Methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

30 9-(2,6,6-Trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

7-Methyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenal;

{5-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-cyclohept-3-enylidene}-acetaldehyde;

35 {4-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-cyclohept-2-enylidene}-acetaldehyde;

- 24 -

4,8-Dimethyl-10-(2,6,6-trimethyl-cyclohex-1-enyl)-
deca-3,5,7,9-tetraen-2-one;

2-Bromo-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenal;

5 2-Fluoro-3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenal;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid;

10 3-Methyl-6-(1,1,4,4-tetramethyl-1,4,5,6,7,7a-hexa-
hydro-inden-2-ylidene)-hexa-2,4-dienoic acid;

3-Methyl-6-(1,1,4,4-tetramethyl-1,4,5,6,7,7a-hexa-
hydro-inden-2-ylidene)-hexa-2,4-dienoic acid;

(E,Z,E,E)-3-tert.-butyl-7-methyl-undec-2,4,6,8-
tetraen-1-ol;

15 3-Methyl-6-(1,1,4,4-tetramethyl-4,5,6,7-tetra-
hydro-1H-inden-2-yl)-hexa-3,5-dienoic acid;

3-Methyl-6-(1,1,4,4-tetramethyl-4,5,6,7-tetra-
hydro-1H-inden-2-yl)-hexa-3,5-dienoic acid;

20 3-Methyl-6-(3,3a,7,7-tetramethyl-4,5,6,7-tetra-
hydro-3aH-inden-2-yl)-hexa-3,5-dienoic acid;

3-Methyl-6-(3,3a,7,7-tetramethyl-4,5,6,7-tetra-
hydro-3aH-inden-2-yl)-hexa-3,5-dienoic acid;

25 3-Methyl-6-(2,4,4-trimethyl-1-methylene-
2,3,4,5,6,7-hexahydro-1H-inden-2-yl)-hexa-2,4-dienoic
acid;


2,3,7-trimethyl-9-(2,6,6-trimethyl-cyclohexa-1,3-
dienyl)-nona-2,4,6,8-tetraenoic acid;

9-(4-dimethylaminophenyl)-2,3,7-trimethyl-nona-
2,4,6,8-tetraenoic acid; and

30 3-Methyl-6-(2,4,4-trimethyl-1-methylene-
2,3,4,5,6,7-hexahydro-1H-inden-2-yl)-hexa-2,4-dienoic
acid.

Additional retinoids which can be utilized are
aryldienoic acids of the general formula


35




-25-

where R_1 is aryl, especially phenyl substituted with further aryl, cycloalkyl, and fused cycloalkylaryl groups.

Preferred retinoids have the formula



where R_1 is aryl, cycloalkyl, or polycyclo of the following general formulas:



Specific retinoids included within the above general formulas include the following:

35

-26-

5- (4-Cycloundecylidenemethyl-phenyl) -3-methyl-
penta-2,4-dienoic acid;

5- (4-Bicyclo[2.2.1]hept-2-ylidenemethyl-phenyl) -
3-methyl-penta-2,4-dienoic acid;

5 5- {4- [2- (4-Methoxy-2,3,6-trimethyl-phenyl) -vinyl] -
phenyl} -3-methyl-penta-2,4-dienoic acid;

2,4-Pentadienoic acid, 3-methyl-5- (2,3,4,4a-tetra-
hydro-4a,10,10-trimethyl-1H-3,9b-methanodibenzofuran-
8-yl) -;

10 3- {4- [2- (4-Methoxy-2,3,6-trimethyl-phenyl) -vinyl] -
phenyl} -acrylic acid;

3- {4- [4- (4-Methoxy-2,3,6-trimethyl-phenyl) -
2-methyl-buta-1,3-dienyl] -phenyl} -acrylic acid;

15 3- {4- [2- (1,3-Dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -phenyl} -
acrylic acid;

3- {4- [Hydroxy- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl) -methyl] -phenyl} -acrylic acid;

20 3- {4- [(4,4-Dimethyl-thiochroman-6-yl) -hydroxy-
methyl] -phenyl} -2-methyl-acrylic acid;

3- [4- (1,2,3,4-Tetrahydro-1,4-methano-naphthalene-
6-carbonyl) -phenyl] -acrylic acid;

3- [4- (2,4-Diisopropyl-benzoyl) -phenyl] -2-methyl-
acrylic acid;

25 3- [4- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalene-2-carbonyl) -phenyl] -acrylic acid;

2-Methyl-3- [4- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalene-2-carbonyl) -phenyl] -acrylic acid;

30 2-Methyl-3- [4- (1,1,2,3,3-pentamethyl-indane-
5-carbonyl-carbonyl) -phenyl] -acrylic acid;

3- [4- (4-Methoxy-2,5-dimethyl-benzoyl) -phenyl] -
2-methyl-acrylic acid;

{2- [3-Methyl-5- (2,6,6-trimethyl-cyclohex-1-enyl) -
penta-2,4-dienylidene] -cycloheptylidene} -acetaldehyde;

-27-

2-Methyl-3- [3-methyl-5- (2,6,6-trimethyl-cyclohex-1-enyl) -penta-2,4-dienylidene] -cyclopent-1-enecarbaldehyde;

3-Methyl-4- {3- [2- (2,6,6-trimethyl-cyclohex-1-enyl) -vinyl] -cyclohex-2-enylidene} -but-2-enal;


{2- [3-Methyl-5- (2,6,6-trimethyl-cyclohex-1-enyl) -penta-2,4-dienylidene] -cyclohexylidene} -acetaldehyde;

{3- [2-Methyl-4- (2,6,6-trimethyl-cyclohex-1-enyl) -buta-1,3-dienyl] -cyclohex-2-enylidene} -acetaldehyde;


{4- [1-Methyl-3- (2,6,6-trimethyl-cyclohex-1-enyl) -allylidene] -cyclohept-2-enylidene} -acetaldehyde; and

{4- [1-Methyl-3- (2,6,6-trimethyl-cyclohex-1-enyl) -allylidene] -cyclopent-2-enylidene} -acetaldehyde.

Still other compounds which are included within the general class of retinoids are retinoidal oxiranes, such as



with preferred oximes having the formula:



Typical retinoidal oxiranes include

4- [3- (4-tert-Butyl-phenyl) -oxiranyl] -benzoic acid;

4- [3- (3-tert-Butyl-phenyl) -oxiranyl] -benzoic acid;

4- [3- (3,4-Diethyl-phenyl) -3-methyl-oxiranyl] -


benzoic acid; and

-28-


4-[3-Methyl-3-(5,5,8,8-tetra-methyl-5,6,7,8-tetra-hydro-naphthalen-2-yl)-oxiranyl]-benzoic acid.

Related compounds are diketones, diols, and acetonides of the formula


5



10




15



20


Certain retinoids have a carboxyamide linkage rather than an alkylene or oxidized alkylene. For example, carboxamide retinoids which can be utilized include those of the formula

25



-29-

where R_1 is an organic radical and includes groups such as



Typical carboxamide retinoids which can be utilized include

- 20 4-benzoylamino-benzoic acid;
 4-(3-tert-Butyl-benzoylamino)-benzoic acid;
 4-(4-tert-Butyl-benzoylamino)-benzoic acid;
 4-(3,5-Di-tert-butyl-benzoylamino)-benzoic acid;
 4-(3,4-Diisopropyl-benzoylamino)-benzoic acid;
 25 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid;
 4-[Methyl-5,5,8,8-tetramethyl-5,6,7,8-tetra-hydro-naphthalene-2-carbonyl)-amino]-benzoic acid;
 4-[(4,4-Dimethyl-chroman-7-carbonyl)-amino]-
 30 benzoic acid;
 4-[(5-Chloro-4,4-dimethyl-chroman-7-carbonyl)-amino]-benzoic acid;
 4-[(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-amino]-benzoic acid;
 35 4-[(3,3-Dimethyl-3,4-dihydro-2H-benzo[b]-[1,4]dioxepine-7-carbonyl)-amino]-benzoic acid;


- 30 -

- 4-[(5-Methyl-2,3,4,5-tetrahydro-benzo[b]thiepine-8-carbonyl)-amino]-benzoic acid;
- 4-[(4,4-Dimethyl-thiochroman-7-carbonyl)-amino]-benzoic acid
- 5 4-[(Thiochroman-6-carbonyl)-amino]-benzoic acid;
- 4-[(2,3-Dihydro-benzo[1,4]dithiine-6-carbonyl)-amino]-benzoic acid;
- 4-[(4,4-Dimethyl-1,1-dioxo-11>6_-thiochroman-7-carbonyl)-amino]-benzoic acid;
- 10 4-[(3-Methyl-1,1-dioxo-11>6_-thiochroman-6-carbonyl)-amino]-benzoic acid;
- 4-[(1,4,4-Trimethyl-1,2,3,4-tetrahydro-quinoline-7-carbonyl)-amino]-benzoic acid;
- 4-[(1-Decyl-4,4-dimethyl-1,2,3,4-tetrahydro-quinoline-7-carbonyl)-amino]-benzoic acid;
- 15 4-(3-tert-Butyl-4-methoxy-benzoylamino)-benzoic acid;
- 4-(3-Adamantan-1-yl-4-hydroxy-benzoylamino)-benzoic acid;
- 20 4-(3-Adamantan-1-yl-4-methoxy-benzoylamino)-benzoic acid;
- 4-(3-Adamantan-1-yl-4-methoxy-benzoylamino)-2-hydroxy-benzoic acid;
- 4-(3-Adamantan-1-yl-4-hexyloxy-benzoylamino)-benzoic acid;
- 25 4-(3-Adamantan-1-yl-4-decyloxy-benzoylamino)-benzoic acid;
- 4-[3-(1,1-Dimethyl-decyl)-4-methoxy-benzoylamino]-benzoic acid;
- 30 N-Phenyl-terephthalamic acid;
- N-m-Tolyl-terephthalamic acid;
- N-(3-Ethyl-phenyl)-terephthalamic acid;
- N-(3-Isopropyl-phenyl)-terephthalamic acid;
- N-(4-Isopropyl-phenyl)-terephthalamic acid;
- 35 N-(3-tert-Butyl-phenyl)-terephthalamic acid;
- N-(4-tert-Butyl-phenyl)-terephthalamic acid;

- 31 -


N- (3-Cyclohexyl-phenyl)-terephthalamic acid;
 N-Biphenyl-3-yl-terephthalamic acid;
 N- (3-Bromo-phenyl)-terephthalamic acid;
 N- (3-Dimethylamino-phenyl)-terephthalamic acid;
 5 N- (3-Trifluoromethyl-phenyl)-terephthalamic acid;
 N- (3,4-Diethyl-phenyl)-terephthalamic acid;
 N- (2-Isopropyl-phenyl)-terephthalamic acid;
 N- (2,4-Diisopropyl-phenyl)-terephthalamic acid;
 N- (2,5-Diisopropyl-phenyl)-terephthalamic acid;
 10 N- (2,6-Diisopropyl-phenyl)-terephthalamic acid;
 N- (3,4-Diisopropyl-phenyl)-terephthalamic acid;
 N- (3,5-Diisopropyl-phenyl)-terephthalamic acid;
 N- (2,4-Di-tert-butyl-phenyl)-terephthalamic acid;
 N- (3,5-Di-tert-butyl-phenyl)-terephthalamic acid;
 15 N- (3,4-Dichloro-phenyl)-terephthalamic acid;
 N- (5,6,7,8-Tetrahydro-naphthalen-1-yl)-tereph-
 thalamic acid;
 N- (5,6,7,8-Tetrahydro-naphthalen-2-yl)-tereph-
 thalamic acid;
 20 N- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naph-
 thalen-1-yl)-terephthalamic acid;
 N- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naph-
 thalen-2-yl)-terephthalamic acid;
 N- (3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-naph-
 25 thalen-2-yl)-terephthalamic acid;
 N-Methyl-N- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
 hydro-naphthalen-2-yl)-terephthalamic acid;
 N-Isopropyl-N- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
 hydro-naphthalen-2-yl)-terephthalamic acid; and
 30 N- (3-Bromo-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
 naphthalen-2-yl)-terephthalamic acid.

Retinoids similar to the carboxamides are carboxy esters such as




- 32 -

and



for example, where R_1 includes



15

As noted before, any of these groups can be substituted in the ring system by R_2 and R_2' , as well as by other art-recognized substituent groups.

20 Typical (aroyloxy) benzoic acids and thio acids which can be utilized include

Benzoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, carboxyphenyl ester;

Benzoic acid, 4-ethyl-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

25 Benzoic acid, 4-ethenyl-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

30 Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxy-3-methylphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxy-2-(hydroxymethyl)phenyl ester;

4-(4-Adamantan-1-yl-3-methoxy-benzoyloxy)-isophthalic acid;

35 Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxy-3-hydroxyphenyl ester;

-33-

Benzoic acid, 2,4-dimethoxy-5-(tricyclo-[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxy-2-methoxyphenyl ester;

5 Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxy-3-methoxyphenyl ester;

Benzoic acid, 2-fluoro-4-methoxy-5-(tricyclo-[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

10 Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxy-3-fluorophenyl ester;

Benzoic acid, 4-(2-propenyloxy)-3-(tricyclo-[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

Benzoic acid, 4-(acetyloxy)-3-(tricyclo-[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

15 Benzoic acid, 4-(2-methoxy-2-oxoethoxy)-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

Benzoic acid, 4-[2-(phenylmethoxy)-2-oxoethoxy]-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

20 Benzoic acid, 4-(methylsulfonyl)-3-(tricyclo-[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;

4,4-Dimethyl-chroman-6-carboxylic acid;

4-ethoxycarbonyl-phenyl ester;

2,2,4,4-Tetramethyl-chroman-6-carboxylic acid;

4-ethoxycarbonyl-phenyl ester;

25 2,2,4,4,7-Pentamethyl-chroman-6-carboxylic acid;

4-ethoxycarbonyl-phenyl ester;

4,4,7-Trimethyl-thiochroman-6-carboxylic acid;

4-ethoxycarbonyl-phenyl ester;

2,2,4,4-Tetramethyl-thiochroman-6-carboxylic acid;

30 4-ethoxycarbonyl-phenyl ester;

4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonylsulfanyl)-benzoic acid;


4-(3-Isopropyl-4-methoxy-benzoylsulfanyl)-benzoic acid;

35 4-(3-Isopropylsulfanyl-4-methyl-benzoylsulfanyl)-benzoic acid;

- 34 -

4- (3-Adamantan-1-yl-benzoylsulfanyl)-benzoic acid;
 4- (5-Adamantan-1-yl-2-fluoro-4-methoxy-benzoyl-
 sulfanyl)-benzoic acid;
 4- (5-Adamantan-1-yl-4-methoxy-2-methyl-benzoyl-
 sulfanyl)-benzoic acid;
 4- (3-Adamantan-1-yl-4-allyloxy-benzoylsulfanyl)-
 benzoic acid;
 4- (3-Adamantan-1-yl-4-methylsulfanyl-benzoyl-
 sulfanyl)-benzoic acid; and
 4- (3,5-Bis-trifluoromethyl-benzoylsulfanyl)-
 benzoic acid.

Other benzoic acid derivatives which are retinoids
 and which can be utilized to lower Lp(a) according to
 this invention include (arylmethyl)amino benzoic acid,
 for example, compounds of the formulas



where aryl is an aromatic radical such as phenyl,
 naphthyl, thienyl, or the like, optionally substituted
 with from 1 to 5 substituents such as alkyl, alkenyl,
 alkynyl, halo, nitro, amino, mono- or dialkylamino,
 hydroxy, and the like, and R₃ and R₄ are hydrogen,
 alkyl, alkenyl, alkynyl, or the like.

Typical aryl methylamino benzoic acid retinoids
 from this class include

4- (4-tert-Butyl-benzylamino)-benzoic acid;
 4- (3,5-Di-tert-butyl-4-hydroxy-benzylamino)-
 benzoic acid;
 4- (4-tert-Butoxy-3-methoxy-benzylamino)-benzoic
 acid;
 4- [4- (1-Methoxy-1-methyl-ethyl)-benzylamino]-
 benzoic acid;

-35-

4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[(3-Fluoro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

5 4-[(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[(1,3-Dimethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

10 4-[(1-Butoxy-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[(5,5,8,8-Tetramethyl-5,8-dihydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[(5,5,8,8-Tetramethyl-7-oxo-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

15 4-[(7-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[1-(7-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylamino]-benzoic acid;

20 4-[Methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[Acetyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethyl)-amino]-benzoic acid;

4-[(5-tert-Butyl-2-methyl-phenylamino)-methyl]-benzoic acid;

25 4-[(3,5-Di-tert-butyl-phenylamino)-methyl]-benzoic acid;

4-[(4-tert-Butyl-2,6-dimethyl-phenylamino)-methyl]-benzoic acid;

30 4-[(1,1,2,3,3-Pentamethyl-indan-5-ylamino)-methyl]-benzoic acid;

4-[1-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylamino)-ethyl]-benzoic acid;

4-[(1,4-Dichloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylamino)-methyl]-benzoic acid;


-36-

4-[(1,4-Dimethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylamino)-methyl]-benzoic acid;
and

4-{[Acetyl-(1,4-dimethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-amino]-methyl}-benzoic acid.

Another preferred group of retinoids that are effective in lowering Lp(a) include (aryloxy)methyl benzoic acid of the formulas

10



15

Typical members of this class include

4-(4-tert-Butyl-phenoxy)methyl)-benzoic acid;

4-(3-tert-Butyl-phenoxy)methyl)-benzoic acid;

20 4-[4-(1,1-Dimethyl-propyl)-phenoxy)methyl]-benzoic acid;

4-(2-tert-Butyl-4-methyl-phenoxy)methyl)-benzoic acid;

25 4-(4-tert-Butyl-2-methyl-phenoxy)methyl)-benzoic acid;

4-(2,4-Di-tert-butyl-phenoxy)methyl)-benzoic acid;

4-(2,6-Di-tert-butyl-phenoxy)methyl)-benzoic acid;

4-(2,5-Di-tert-butyl-phenoxy)methyl)-benzoic acid;

4-(3,5-Di-tert-butyl-phenoxy)methyl)-benzoic acid;

30 4-(2-sec-Butyl-4-tert-butyl-phenoxy)methyl)-benzoic acid;

4-(2,4-Di-tert-butyl-5-methyl-phenoxy)methyl)-benzoic acid;

35 4-(2,4,6-Tri-tert-butyl-phenoxy)methyl)-benzoic acid;

-37-

4- (3,5-Di-tert-butyl-2-hydroxy-phenoxy-methyl) -
benzoic acid;

4- (5,5,8,8-Tetramethyl-3-nitro-5,6,7,8-tetrahydro-
naphthalen-2-yloxy-methyl) -benzoic acid;

5 4- (1,4-Dihydroxy-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-naphthalen-2-yloxy-methyl) -benzoic acid;

4- (1,4-Diacetoxy-5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-naphthalen-2-yloxy-methyl) -benzoic acid;

10 4- (2,2,5,7,8-Pentamethyl-chroman-6-yloxy-methyl) -
benzoic acid;

4- [2- (2-Hydroxy-ethyl) -2,5,7,8-tetramethyl-
chroman-6-yloxy-methyl] -benzoic acid; and

4- [2- (2-Acetoxy-ethyl) -2,5,7,8-tetramethyl-
chroman-6-yloxy-methyl] -benzoic acid.

15 Similar compounds which have sulfur in the linkage
instead of oxygen include the following

4- (4-tert-Butyl-phenylsulfanylmethyl) -benzoic
acid;

20 4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;


4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

25 4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid; and

4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid.


30 Like the carboxamides and esters, some retinoids
have more than one nitrogen in the linking chain, for
example, there are arylazobenzoic acids such as



35

- 38 -


and hydrazone-bridge benzoic acids such as



Typical members of this class include

- 10 4- (3,4-Diethyl-phenylazo) -benzoic acid;
 4- (2-Isopropyl-phenylazo) -benzoic acid;
 4- (3-Isopropyl-phenylazo) -benzoic acid;
 4- (4-Isopropyl-phenylazo) -benzoic acid;
 4- (2,4-Diisopropyl-phenylazo) -benzoic acid;
 15 4- (2,6-Diisopropyl-phenylazo) -benzoic acid;
 4- (3,4-Diisopropyl-phenylazo) -benzoic acid;
 4- (3,5-Diisopropyl-phenylazo) -benzoic acid;
 4- (3-tert-Butyl-phenylazo) -benzoic acid;
 4- (3-Cyclohexyl-phenylazo) -benzoic acid;
 20 4- (Biphenyl-3-ylazo) -benzoic acid;
 4- (4,4-Dimethyl-thiochroman-6-ylazo) -benzoic acid;
 4- [2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
 hydro-naphthalen-2-yl) -ethylamino] -benzoic acid;
 4- [2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
 25 hydro-naphthalen-2-yl) -ethylsulfanyl] -benzoic acid;
 4- [2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
 hydro-naphthalen-2-yl) -ethoxy] -benzoic acid;
 4- [N' - (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
 naphthalen-2-ylmethylene) -hydrazino] -benzoic acid; and
 30 4- {N' - [Cyclopropyl - (1,1,2,3,3-pentamethyl-indan-
 5-yl) -methylene] -hydrazino} -benzoic acid.

A particular preferred class of retinoid compounds to be utilized to lower Lp(a) according to this invention include polyenoic acids and esters such as



- 39 -

where aryl is an unsubstituted or substituted aromatic or cyclic radical such as phenyl, naphthyl, piperidyl, morpholinyl, or the like, and ester is preferably an alkyl group such as methyl, ethyl, isobutyl, or the like. Typical polyenoic retinoids include the following

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid methyl ester;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid 2-{2-[2-(2-hydroxyethoxy)-ethoxy]-ethoxy}-ethyl ester;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid 2-{2-[2-(2-hydroxyethoxy)-ethoxy]-ethoxy}-ethyl ester;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid 2-(2-oxo-pyrrolidin-1-yl)-ethyl ester;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid 2-(2-oxo-pyrrolidin-1-yl)-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-{2-[2-(2-hydroxyethoxy)-ethoxy]-ethoxy}-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-piperidin-1-yl-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-morpholin-4-yl-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-piperidin-1-yl-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(2,5-dioxo-pyrrolidin-1-yl)-ethyl ester;

-40-

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(2,6-dioxo-cyclohexyl)-ethyl ester;

5 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-methanesulfonyl-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid methoxycarbonylmethyl ester;

10 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid tert-butoxycarbonylmethyl ester;

15 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid phenoxycarbonylmethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-acetoxy-phenoxycarbonylmethyl ester;

20 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid styryloxycarbonylmethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(4-methoxy-phenyl)-vinylloxycarbonylmethyl ester;

25 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(benzoyl-carbonyl)-5-methoxy-phenoxymethoxycarbonyl-methyl ester;

30 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 1-phenoxycarbonyl-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 1-ethoxycarbonyloxy-ethyl ester;

35 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid 2-butoxy-4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester;

-41-

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 2-butoxy-4-dimethylamino-
6-methyl-tetrahydro-pyran-3-yl ester;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 2-butoxy-4-dimethylamino-
6-methyl-tetrahydro-pyran-3-yl ester;


3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 4-dimethylamino-6-methyl-
2-(2-octyl-hexadecyloxy)-tetrahydro-pyran-3-yl ester;

9-(4-Methoxy-2,5,6-trimethyl-cyclohex-1-enyl)-
3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-butoxy-
4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester;

9-(4-Methoxy-2,5,6-trimethyl-cyclohex-1-enyl)-
3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-butoxy-
4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester;
and


9-(4-Methoxy-2,5,6-trimethyl-cyclohex-1-enyl)-
3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-butoxy-
4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester.

In addition to retinoic acids and esters, the
method of this invention can be practiced with retinoid
amides, for example, any of the foregoing compounds in
an amide form, eg, the general formula



where R_3 and R_4 independently are hydrogen, $\text{C}_1\text{-C}_6$
alkyl, phenyl, or $\text{R}_2\text{R}_2'$ substituted or disubstituted
phenyl, or taken together with the nitrogen to which
they are attached, R_3 and R_4 complete a ring which can
have 1 or 2 heteroatoms, such as oxygen, sulfur, or
nitrogen. Typical retinoids of this type include

- 42 -



-43-

Examples of specific retinoids having the above structures include the following

4- [4- (2,6,6-Trimethyl-cyclohex-1-enyl) -but-3-en-1-ynyl] -benzamide;

5 3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoic acid amide;

 [6- (3-Adamantan-1-yl-4-methoxy-phenyl) -naphthalen-2-yl] -morpholin-4-yl-methanone;

10 N- (3,5-Bis-trifluoromethyl-phenyl) -4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -benzamide;

 N- (4-Hydroxy-phenyl) -4- [2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -benzamide;

15 N- (3,5-Bis-trifluoromethyl-phenyl) -4- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -benzamide;

 [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -acetic acid;

20 [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -acetic acid methyl ester;

 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -4-methyl-pentanoic acid;

25 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -3-phenyl-propionic acid;

 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -3- (4-hydroxy-phenyl) -propionic acid;

30 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -pentanedioic acid;

 [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -acetic acid;

35 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -propionic acid;

- 44 -

2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -4-methyl-pentanoic acid;

5 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -3-phenyl-propionic acid;

4- [3,7-Dimethyl-9- (3,3,6,6-tetramethyl-cyclohex-1-enyl) -nona-2,4,6-trien-8-ynoylamino] -benzoic acid;

10 2- [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoyl] -benzo[d]isothiazol-3-one;

4- [2- (8,8-Dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -propenyl] -N- (1H-tetrazol-5-yl) -benzamide;

15 [3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoylamino] -acetic acid;

4-Methyl-7- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -octa-2,4,6-trienoic acid ethylamide;

20 {4- [4- (2-Hydroxy-ethyl) -piperazine-1-carbonyl] -phenyl} - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -methanone;

6- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -naphthalene-2-carboxylic acid; [2- (2-hydroxy-ethoxy) -ethyl] -amide;

25 6- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -naphthalene-2-carboxylic acid (4-hydroxy-phenyl) -amide;

30 4-Methylsulfanyl-2- { [6- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -naphthalene-2-carbonyl] -amino} -butyric acid;

5- (4-Adamantan-2-ylidenemethyl-phenyl) -3-methyl-penta-2,4-dienoic acid (2-ethyl-hexyl) -amide;

35 2- [5- (4-Adamantan-2-ylidenemethyl-phenyl) -3-methyl-penta-2,4-dienoylamino] -4-methylsulfanyl-butyric acid ethyl ester;

- 45 -


4- [2- (1,3-Dimethoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -N- (2-hydroxy-ethyl) -benzamide;

N-Butyl-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -benzamide;

N- (2-Hydroxy-ethyl) -2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -benzamide;
and

{2- [4- (2-Hydroxy-ethyl) -piperazine-1-carbonyl-carbonyl] -phenyl} - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -methanone.

An especially preferred group of retinoids for lowering Lp(a) are adamantyl substituted benzamides which can be prepared by reacting a compound such as 3-adamantan-1-yl-4-methoxy-benzoyl chloride with a 4-aminobenzamide according to the following sequence



where R_1 and R_2 can be organic radicals such as C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_6 cycloalkyl, and the like, or together with the nitrogen form a cyclic ring such as pyrrolidine or the like.

Typical amino benzamide starting materials include

4-Amino-N-tert-butyl-benzamide;

4-Amino-N-phenyl-benzamide;

4-Amino-N-benzyl-benzamide;

4-Amino-N- (2-hydroxy-ethyl) -benzamide;

(4-Amino-phenyl) -pyrrolidin-1-yl-methanone;

(4-Amino-phenyl) -piperidin-1-yl-methanone; and

(4-Amino-phenyl) -morpholin-4-yl-methanone.

Typical retinoids prepared as described above

include

-46-

Benzamide, N-[4-[(1,1-dimethylethyl)amino]-carbonyl]phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

5 Benzamide, N-[4-[(phenylamino)carbonyl]phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

Benzamide, N-[4-[(phenylmethyl)amino]carbonyl]-phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

Benzamide, N-[4-[(2-hydroxyethyl)amino]carbonyl]-phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

10 3-Adamantan-1-yl-4-methoxy-N-[4-(pyrrolidine-1-carbonyl-carbonyl)-phenyl]-benzamide;

3-Adamantan-1-yl-4-methoxy-N-[4-(piperidine-1-carbonyl-carbonyl)-phenyl]-benzamide; and

15 3-Adamantan-1-yl-4-methoxy-N-[4-(morpholine-4-carbonyl-carbonyl)-phenyl]-benzamide.

The following specific retinoids are also useful in the method of this invention:

4-[3-(4-tert-Butyl-phenyl)-oxiranyl]-benzoic acid;

4-[3-(3-tert-Butyl-phenyl)-oxiranyl]-benzoic acid;

20 4-[3-(3,4-Diethyl-phenyl)-3-methyl-oxiranyl]-benzoic acid;

4-[3-Methyl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-oxiranyl]-benzoic acid;

4-Benzoylamino-benzoic acid;

25 4-(3-tert-Butyl-benzoylamino)-benzoic acid;

4-(4-tert-Butyl-benzoylamino)-benzoic acid;

4-(3,5-Di-tert-butyl-benzoylamino)-benzoic acid;

4-(3,4-Diisopropyl-benzoylamino)-benzoic acid;

30 4-[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid;

4-[Methyl-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carbonyl)-amino]-benzoic acid;

4-[(4,4-Dimethyl-chroman-7-carbonyl)-amino]-benzoic acid;

35 4-[(5-Chloro-4,4-dimethyl-chroman-7-carbonyl)-amino]-benzoic acid;

- 47 -

4-[(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-amino]-benzoic acid;

4-[(3,3-Dimethyl-3,4-dihydro-2H-benzo[b][1,4]-dioxepine-7-carbonyl)-amino]-benzoic acid;

5 4-[(5-Methyl-2,3,4,5-tetrahydro-benzo[b]thiepine-8-carbonyl)-amino]-benzoic acid;

4-[(4,4-Dimethyl-thiochroman-7-carbonyl)-amino]-benzoic acid;

4-[(Thiochroman-6-carbonyl)-amino]-benzoic acid;

10 4-[(2,3-Dihydro-benzo[1,4]dithiine-6-carbonyl)-amino]-benzoic acid;

4-[(4,4-Dimethyl-1,1-dioxo-11>6_-thiochroman-7-carbonyl)-amino]-benzoic acid;

15 4-[(3-Methyl-1,1-dioxo-11>6_-thiochroman-6-carbonyl)-amino]-benzoic acid;

4-[(1,4,4-Trimethyl-1,2,3,4-tetrahydro-quinoline-7-carbonyl)-amino]-benzoic acid;

4-[(1-Decyl-4,4-dimethyl-1,2,3,4-tetrahydro-quinoline-7-carbonyl)-amino]-benzoic acid;

20 4-(3-tert-Butyl-4-methoxy-benzoylamino)-benzoic acid;

4-(3-Adamantan-1-yl-4-hydroxy-benzoylamino)-benzoic acid;

25 4-(3-Adamantan-1-yl-4-methoxy-benzoylamino)-benzoic acid;

4-(3-Adamantan-1-yl-4-methoxy-benzoylamino)-2-hydroxy-benzoic acid;

4-(3-Adamantan-1-yl-4-hexyloxy-benzoylamino)-benzoic acid;

30 4-(3-Adamantan-1-yl-4-decyloxy-benzoylamino)-benzoic acid;

IUPAC: 4-[3-(1,1-Dimethyl-decyl)-4-methoxy-benzoylamino]-benzoic acid;

35 N-Phenyl-terephthalamic acid;

N-m-Tolyl-terephthalamic acid;

-48-

- N- (3-Ethyl-phenyl)-terephthalamic acid;
N- (3-Isopropyl-phenyl)-terephthalamic acid;
N- (4-Isopropyl-phenyl)-terephthalamic acid;
N- (3-tert-Butyl-phenyl)-terephthalamic acid;
5 N- (4-tert-Butyl-phenyl)-terephthalamic acid;
N- (3-Cyclohexyl-phenyl)-terephthalamic acid;
N-Biphenyl-3-yl-terephthalamic acid;
N- (3-Bromo-phenyl)-terephthalamic acid;
N- (3-Dimethylamino-phenyl)-terephthalamic acid;
10 N- (3-Trifluoromethyl-phenyl)-terephthalamic acid;
N- (3,4-Diethyl-phenyl)-terephthalamic acid;
N- (2-Isopropyl-phenyl)-terephthalamic acid;
N- (2,4-Diisopropyl-phenyl)-terephthalamic acid;
N- (2,5-Diisopropyl-phenyl)-terephthalamic acid;
15 N- (2,6-Diisopropyl-phenyl)-terephthalamic acid;
N- (3,4-Diisopropyl-phenyl)-terephthalamic acid;
N- (3,5-Diisopropyl-phenyl)-terephthalamic acid;
N- (2,4-Di-tert-butyl-phenyl)-terephthalamic acid;
N- (3,5-Di-tert-butyl-phenyl)-terephthalamic acid;
20 N- (3,4-Dichloro-phenyl)-terephthalamic acid;
N- (5,6,7,8-Tetrahydro-naphthalen-1-yl)-
terephthalamic acid;
N- (5,6,7,8-Tetrahydro-naphthalen-2-yl)-
terephthalamic acid;
25 N- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-1-yl)-terephthalamic acid;
N- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-terephthalamic acid;
N- (3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-
30 naphthalen-2-yl)-terephthalamic acid;
N-Methyl-N- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl)-terephthalamic acid;
N-Isopropyl-N- (5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl)-terephthalamic acid;
35 N- (3-Bromo-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-terephthalamic acid;

- 49 -

N- (3-Amino-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl) -terephthalamic acid;

N- (5,5,8,8-Tetramethyl-3-nitro-5,6,7,8-tetrahydro-naphthalen-2-yl) -terephthalamic acid;

5 N- (4,4-Dimethyl-chroman-6-yl) -terephthalamic acid;

N- (4,4-Dimethyl-thiochroman-6-yl) -terephthalamic acid;

Benzoic acid, 3,5-bis(1,1-dimethylethyl) -4-hydroxy-, carboxyphenyl ester;

10 Benzoic acid, 4-ethyl-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxyphenyl ester;

Benzoic acid, 4-ethenyl-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxyphenyl ester;

15 Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxyphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxy-3-methylphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxy-2-(hydroxymethyl)phenyl ester;

20 4-(4-Adamantan-1-yl-3-methoxy-benzoyloxy) -isophthalic acid;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxy-3-hydroxyphenyl ester;

25 Benzoic acid, 2,4-dimethoxy-5-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxyphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxy-2-methoxyphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxy-3-methoxyphenyl ester;

30 Benzoic acid, 2-fluoro-4-methoxy-5-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxyphenyl ester;

Benzoic acid, 4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxy-3-fluorophenyl ester;

35 Benzoic acid, 4-(2-propenyloxy)-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl) -, 4-carboxyphenyl ester;

-50-

- Benzoic acid, 4-(acetyloxy)-3-(tricyclo-
[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;
- Benzoic acid, 4-(2-methoxy-2-oxoethoxy)-3-
(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;
- 5 Benzoic acid, 4-[2-(phenylmethoxy)-2-oxoethoxy]-3-
(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;
- Benzoic acid, 4-(methylsulfonyl)-3-(tricyclo-
[3.3.1.1^{3,7}]dec-1-yl)-, 4-carboxyphenyl ester;
- 4,4-Dimethyl-chroman-6-carboxylic acid
- 10 4-ethoxycarbonyl-phenyl ester;
- 2,2,4,4-Tetramethyl-chroman-6-carboxylic acid
- 4-ethoxycarbonyl-phenyl ester;
- 2,2,4,4,7-Pentamethyl-chroman-6-carboxylic acid
- 4-ethoxycarbonyl-phenyl ester;
- 15 4,4,7-Trimethyl-thiochroman-6-carboxylic acid
- 4-ethoxycarbonyl-phenyl ester;
- 2,2,4,4-Tetramethyl-thiochroman-6-carboxylic acid
- 4-ethoxycarbonyl-phenyl ester;
- 4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
- 20 naphthalene-2-carbonylsulfanyl)-benzoic acid;
- 4-(3-Isopropyl-4-methoxy-benzoylsulfanyl)-benzoic
acid;
- 4-(3-Isopropylsulfanyl-4-methyl-benzoylsulfanyl)-
benzoic acid;
- 25 4-(3-Adamantan-1-yl-benzoylsulfanyl)-benzoic acid;
- 4-(5-Adamantan-1-yl-2-fluoro-4-methoxy-benzoyl-
sulfanyl)-benzoic acid;
- 4-(5-Adamantan-1-yl-4-methoxy-2-methyl-
benzoylsulfanyl)-benzoic acid;
- 30 4-(3-Adamantan-1-yl-4-allyloxy-benzoylsulfanyl)-
benzoic acid;
- 4-(3-Adamantan-1-yl-4-methylsulfanyl-
benzoylsulfanyl)-benzoic acid;
- 4-(3,5-Bis-trifluoromethyl-benzoylsulfanyl)-
35 benzoic acid;
- 4-(4-tert-Butyl-benzylamino)-benzoic acid;

- 51 -

4- (3,5-Di-tert-butyl-4-hydroxy-benzylamino) -
benzoic acid;

4- (4-tert-Butoxy-3-methoxy-benzylamino) -benzoic
acid;

5 4- [4- (1-Methoxy-1-methyl-ethyl) -benzylamino] -
benzoic acid;

4- [(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-ylmethyl) -amino] -benzoic acid;

10 4- [(3-Fluoro-5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-ylmethyl) -amino] -benzoic acid;

4- [(3-Methoxy-5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-ylmethyl) -amino] -benzoic acid;

15 4- [(1,3-Dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-ylmethyl) -amino] -
benzoic acid;

4- [(1-Butoxy-3,5,5,8,8-pentamethyl-5,6,7,8-tetra-
hydro-naphthalen-2-ylmethyl) -amino] -benzoic acid;

4- [(5,5,8,8-Tetramethyl-5,8-dihydro-naphthalen-
2-ylmethyl) -amino] -benzoic acid;

20 4- [(5,5,8,8-Tetramethyl-7-oxo-5,6,7,8-tetrahydro-
naphthalen-2-ylmethyl) -amino] -benzoic acid;

4- [(7-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-ylmethyl) -amino] -benzoic acid;

25 4- [1- (7-Hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl) -ethylamino] -benzoic acid;

4- [Methyl- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-ylmethyl) -amino] -benzoic acid;

4- [Acetyl- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-ylmethyl) -amino] -benzoic acid;

30 4- [(5-tert-Butyl-2-methyl-phenylamino) -methyl] -
benzoic acid;

4- [(3,5-Di-tert-butyl-phenylamino) -methyl] -benzoic
acid;

35 4- [(4-tert-Butyl-2,6-dimethyl-phenylamino) -
methyl] -benzoic acid;

- 52 -

- 4- [(1,1,2,3,3-Pentamethyl-indan-5-ylamino) -
methyl] -benzoic acid;
- 4- [1- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-ylamino) -ethyl] -benzoic acid;
- 5 4- [(1,4-Dichloro-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-ylamino) -methyl] -
benzoic acid;
- 4- [(1,4-Dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-ylamino) -methyl] -
10 benzoic acid;
- 4- { [Acetyl- (1,4-dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -amino] -methyl} -
benzoic acid;
- 4- (4-tert-Butyl-phenoxyethyl) -benzoic acid;
- 15 4- (3-tert-Butyl-phenoxyethyl) -benzoic acid;
- 4- [4- (1,1-Dimethyl-propyl) -phenoxyethyl] -benzoic
acid;
- 4- (2-tert-Butyl-4-methyl-phenoxyethyl) -benzoic
acid;
- 20 4- (4-tert-Butyl-2-methyl-phenoxyethyl) -benzoic
acid;
- 4- (2,4-Di-tert-butyl-phenoxyethyl) -benzoic acid;
- 4- (2,6-Di-tert-butyl-phenoxyethyl) -benzoic acid;
- 4- (2,5-Di-tert-butyl-phenoxyethyl) -benzoic acid;
- 25 4- (3,5-Di-tert-butyl-phenoxyethyl) -benzoic acid;
- 4- (2-sec-Butyl-4-tert-butyl-phenoxyethyl) -benzoic
acid;
- 4- (2,4-Di-tert-butyl-5-methyl-phenoxyethyl) -
benzoic acid;
- 30 4- (2,4,6-Tri-tert-butyl-phenoxyethyl) -benzoic
acid;
- 4- (3,5-Di-tert-butyl-2-hydroxy-phenoxyethyl) -
benzoic acid;
- 4- (5,5,8,8-Tetramethyl-3-nitro-5,6,7,8-tetrahydro-
35 naphthalen-2-ylmethoxy) -benzoic acid;

-53-

4- (1,4-Dihydroxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl) -benzoic
acid;

5 4- (1,4-Diacetoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl) -benzoic
acid;

4- (2,2,5,7,8-Pentamethyl-chroman-6-yloxymethyl) -
benzoic acid;

10 4- [2- (2-Hydroxy-ethyl) -2,5,7,8-tetramethyl-
chroman-6-yloxymethyl] -benzoic acid;

4- [2- (2-Acetoxy-ethyl) -2,5,7,8-tetramethyl-
chroman-6-yloxymethyl] -benzoic acid;

4- (4-tert-Butyl-phenylsulfanylmethyl) -benzoic
acid;

15 4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

20 4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

4- (4-tert-Butyl-2-methyl-phenylsulfanylmethyl) -
benzoic acid;

25 4- (3,4-Diethyl-phenylazo) -benzoic acid;

4- (2-Isopropyl-phenylazo) -benzoic acid;

4- (3-Isopropyl-phenylazo) -benzoic acid;

4- (4-Isopropyl-phenylazo) -benzoic acid;

4- (2,4-Diisopropyl-phenylazo) -benzoic acid;

30 4- (2,6-Diisopropyl-phenylazo) -benzoic acid;

4- (3,4-Diisopropyl-phenylazo) -benzoic acid;

4- (3,5-Diisopropyl-phenylazo) -benzoic acid;

4- (3-tert-Butyl-phenylazo) -benzoic acid;

4- (3-Cyclohexyl-phenylazo) -benzoic acid;

35 4- (Biphenyl-3-ylazo) -benzoic acid;

4- (4,4-Dimethyl-thiochroman-6-ylazo) -benzoic acid;

- 54 -

- 4- [2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylamino]-benzoic acid;
- 4- [2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylsulfanyl]-benzoic acid;
- 5 4- [2-Hydroxy-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethoxy]-benzoic acid;
- 4- [N' - (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylmethylene)-hydrazino]-benzoic acid;
- 4- {N' - [Cyclopropyl- (1,1,2,3,3-pentamethyl-indan-5-yl)-methylene]-hydrazino}-benzoic acid;
- 10 3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoic acid 2- {2- [2- (2-hydroxy-ethoxy) -ethoxy] -ethoxy} -ethyl ester;
- 3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoic acid 2- {2- [2- (2-hydroxy-ethoxy) -ethoxy] -ethoxy} -ethyl ester;
- 15 3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoic acid 2- (2-oxo-pyrrolidin-1-yl) -ethyl ester;
- 20 3,7-Dimethyl-9- (2,6,6-trimethyl-cyclohex-1-enyl) -nona-2,4,6,8-tetraenoic acid 2- (2-oxo-pyrrolidin-1-yl) -ethyl ester;
- 9- (4-Methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2- {2- [2- (2-hydroxy-ethoxy) -ethoxy] -ethoxy} -ethyl ester;
- 25 9- (4-Methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-piperidin-1-yl-ethyl ester;
- 9- (4-Methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-morpholin-4-yl-ethyl ester;
- 30 9- (4-Methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-piperidin-1-yl-ethyl ester;

-55-

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(2,5-dioxo-pyrrolidin-1-yl)-ethyl ester;

5 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(2,6-dioxo-cyclohexyl)-ethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-methanesulfonyl-ethyl ester;

10 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid methoxycarbonylmethyl ester;

15 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid tert-butoxycarbonylmethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid phenoxycarbonylmethyl ester;

20 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-acetoxy-phenoxy-carbonylmethyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid styryloxycarbonylmethyl ester;

25 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(4-methoxy-phenyl)-vinylloxycarbonylmethyl ester;

30 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-(benzoyl-carbonyl)-5-methoxy-phenoxy-methoxycarbonyl-methyl ester;

9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 1-phenoxy-carbonyl-ethyl ester;

35 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 1-ethoxycarbonyloxy-ethyl ester;

- 56 -

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 2-butoxy-4-dimethylamino-
6-methyl-tetrahydro-pyran-3-yl ester;

5 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 2-butoxy-4-dimethylamino-
6-methyl-tetrahydro-pyran-3-yl ester;

3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 2-butoxy-4-dimethylamino-
6-methyl-tetrahydro-pyran-3-yl ester;

10 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid 4-dimethylamino-6-methyl-
2-(2-octyl-hexadecyloxy)-tetrahydro-pyran-3-yl ester;

9-(4-Methoxy-2,5,6-trimethyl-cyclohex-1-enyl)-
3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-butoxy-
15 4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester;

9-(4-Methoxy-2,5,6-trimethyl-cyclohex-1-enyl)-
3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-butoxy-
4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester;

9-(4-Methoxy-2,5,6-trimethyl-cyclohex-1-enyl)-
20 3,7-dimethyl-nona-2,4,6,8-tetraenoic acid 2-butoxy-
4-dimethylamino-6-methyl-tetrahydro-pyran-3-yl ester;

4-[4-(2,6,6-Trimethyl-cyclohex-1-enyl)-but-3-en-
1-ynyl]-benzamide;

25 3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoic acid amide;

[6-(3-Adamantan-1-yl-4-methoxy-phenyl)-naphthalen-
2-yl]-morpholin-4-yl-methanone;

N-(3,5-Bis-trifluoromethyl-phenyl)-4-
(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-
2-carbonyl)-benzamide;

N-(4-Hydroxy-phenyl)-4-[2-(5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl)-vinyl]-benzamide;

N-(3,5-Bis-trifluoromethyl-phenyl)-4-
(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalene-
2-carbonyl)-benzamide;

35

-57-

[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoylamino]-acetic acid;

[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoylamino]-acetic acid;

5 2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-4-methyl-
pentanoic acid;

10 2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-3-phenyl-
propionic acid;

2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-3-(4-hydroxy-
phenyl)-propionic acid;

15 2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-pentanedioic
acid;

[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoylamino]-acetic acid;

20 2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-propionic acid;

2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-4-methyl-
pentanoic acid;

25 2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoylamino]-3-phenyl-
propionic acid;

4-[3,7-Dimethyl-9-(3,3,6,6-tetramethyl-cyclohex-
1-enyl)-nona-2,4,6-trien-8-ynoylamino]-benzoic acid;

30 2-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-
1-enyl)-nona-2,4,6,8-tetraenoyl]-benzo[d]isothiazol-
3-one;

4-[2-(8,8-Dimethyl-5,6,7,8-tetrahydro-naphthalen-
2-yl)-propenyl]-N-(1H-tetrazol-5-yl)-benzamide;

35 [3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-
nona-2,4,6,8-tetraenoylamino]-acetic acid;

-58-

- 4-Methyl-7- (5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -octa-2,4,6-trienoic
acid ethylamide;
- 5 {4- [4- (2-Hydroxy-ethyl) -piperazine-1-carbonyl] -
phenyl} - (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl) -methanone;
- 6- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalene-2-carbonyl) -naphthalene-2-carboxylic acid
[2- (2-hydroxy-ethoxy) -ethyl] -amide;
- 10 6- (5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
naphthalene-2-carbonyl) -naphthalene-2-carboxylic acid
(4-hydroxy-phenyl) -amide;
- 15 4-Methylsulfanyl-2- { [6- (5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -naphthalene-
2-carbonyl] -amino} -butyric acid;
- 5- (4-Adamantan-2-ylidenemethyl-phenyl) -3-methyl-
penta-2,4-dienoic acid (2-ethyl-hexyl) -amide;
- 2- [5- (4-Adamantan-2-ylidenemethyl-phenyl) -
3-methyl-penta-2,4-dienoylamino] -4-methylsulfanyl-
20 butyric acid ethyl ester;
- 4- [2- (1,3-Dimethoxy-5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalen-2-yl) -vinyl] -N-
(2-hydroxy-ethyl) -benzamide;
- N-Butyl-2- (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
25 naphthalene-2-carbonyl) -benzamide;
- N- (2-Hydroxy-ethyl) -2- (5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-naphthalene-2-carbonyl) -benzamide;
- {2- [4- (2-Hydroxy-ethyl) -piperazine-1-carbonyl-
carbonyl] -phenyl} - (5,5,8,8-tetramethyl-5,6,7,8-tetra-
30 hydro-naphthalen-2-yl) -methanone;
- 3-Adamantan-1-yl-4-methoxy-benzoyl chloride;
- 4-Amino-N-tert-butyl-benzamide;
- 4-Amino-N-phenyl-benzamide;
- 4-Amino-N-benzyl-benzamide;
- 35 4-Amino-N- (2-hydroxy-ethyl) -benzamide;
- (4-Amino-phenyl) -pyrrolidin-1-yl-methanone;

- 59 -

(4-Amino-phenyl)-piperidin-1-yl-methanone;

(4-Amino-phenyl)-morpholin-4-yl-methanone;

Benzamide, N-[4-[(1,1-dimethylethyl)amino]carbonyl]phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

Benzamide, N-[4-[(phenylamino)carbonyl]phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

Benzamide, N-[4-[(phenylmethyl)amino]carbonyl]phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

Benzamide, N-[4-[(2-hydroxyethyl)amino]carbonyl]phenyl]-4-methoxy-3-(tricyclo[3.3.1.1^{3,7}]dec-1-yl)-;

3-Adamantan-1-yl-4-methoxy-N-[4-(pyrrolidine-1-carbonyl-carbonyl)-phenyl]-benzamide;

3-Adamantan-1-yl-4-methoxy-N-[4-(piperidine-1-carbonyl-carbonyl)-phenyl]-benzamide;

3-Adamantan-1-yl-4-methoxy-N-[4-(morpholine-4-carbonyl-carbonyl)-phenyl]-benzamide;

1,1,3,3-Tetramethyl-5-(1-methyl-2-phenyl-vinyl)-indan;

6-(1-Methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

6-(1-Methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

1,1-Dimethyl-6-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

1,1,4,4-Tetramethyl-6-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

1,1,4,4,6-Pentamethyl-7-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

1,1,4,4-Tetramethyl-6-(1-methyl-2-phenyl-vinyl)-7-octyl-1,2,3,4-tetrahydro-naphthalene;

6-Methoxy-1,1,4,4-tetramethyl-7-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

6-Chloro-1,1,4,4-tetramethyl-7-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;

-60-

- (Z)-1,1,4,4-Tetramethyl-6-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalene;
- 1,1,4,4-Tetramethyl-6-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalen-2-ol;
- 5 1,1,4,4,6-Pentamethyl-7-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-naphthalen-2-ol;
- 1,1,3,3-Tetramethyl-5-(1-methyl-2-phenyl-vinyl)-indan-2-one;
- 1,4,4-Trimethyl-7-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-quinoline;
- 10 1,4,4-Trimethyl-6-(1-methyl-2-phenyl-vinyl)-1,2,3,4-tetrahydro-quinoline;
- 4,4-Dimethyl-7-(1-methyl-2-phenyl-vinyl)-chroman;
- 4,4-Dimethyl-6-(1-methyl-2-phenyl-vinyl)-chroman;
- 15 450) IUPAC: 4,4-Dimethyl-7-(1-methyl-2-phenyl-vinyl)-thiochroman;
- 4,4-Dimethyl-6-(1-methyl-2-phenyl-vinyl)-thiochroman;
- 4,4-Dimethyl-7-(1-methyl-2-phenyl-vinyl)-thiochroman 1,1-dioxide;
- 20 4,4-Dimethyl-6-(1-methyl-2-phenyl-vinyl)-thiochroman 1,1-dioxide;
- 2,2-Dimethyl-5-(1-methyl-2-phenyl-vinyl)-benzo[1,3]dithiole;
- 25 7,7-Dimethyl-2-(1-methyl-2-phenyl-vinyl)-7,8-dihydro-6H-5,9-dithia-benzocycloheptene;
- 1,1,3,3-Tetramethyl-indan-5-carboxylic acid phenylamide;
- 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid phenylamide;
- 30 5,5,7,7,9,9-Hexamethyl-6,7,8,9-tetrahydro-5H-benzocycloheptene-2-carboxylic acid phenylamide;
- 459) IUPAC: N-(1,1,3,3-Tetramethyl-indan-5-yl)-benzamide;
- 35 N-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-benzamide;

-61-

3-Adamantan-1-yl-4-methoxy-benzoic acid phenyl ester;

3-Adamantan-1-yl-4-methoxy-thiobenzoic acid S-phenyl ester;

5 4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenol;

Acetic acid 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl ester;

10 1-(2-{4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenoxy}-ethyl)-piperidine;

4-(2-{4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenoxy}-ethyl)-morpholine;

4-(2-{4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenoxy}-ethyl)-thiomorpholine 1,1-dioxide;

20 4-[2-(3-Chloro-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenol;

4-[2-(6-Methoxy-1,1,3,3-tetramethyl-indan-5-yl)-propenyl]-phenol;

5-[2-(4-Hydroxy-phenyl)-1-methyl-vinyl]-1,1,3,3-tetramethyl-indan-2-one;

25 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid (4-hydroxy-phenyl)-amide;

7,7-Dimethyl-6,7,8,9-tetrahydro-5H-benzocycloheptene-2-carboxylic acid (4-hydroxy-phenyl)-amide;

30 3-Ethyl-7,7-dimethyl-6,7,8,9-tetrahydro-5H-benzocycloheptene-2-carboxylic acid (4-hydroxy-phenyl)-amide;

4-Hydroxy-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-benzamide;

35 3-Adamantan-1-yl-4-methoxy-benzoic acid 4-hydroxy-phenyl ester;

- 62 -

3-Adamantan-1-yl-4-methoxy-thiobenzoic acid S-(4-hydroxy-phenyl) ester;

5-[2-Methyl-4-(2,6,6-trimethyl-cyclohex-1-enyl)-buta-1,3-dienyl]-1H-tetrazole;

5 {4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl}-1H-tetrazole;

5-[4-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylethynyl)-phenyl]-1H-tetrazole;

10 Methyl-{4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl}-phosphinic acid ethyl ester;

Phenyl-{4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl}-phosphinic acid ethyl ester;

15 {4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl}-phosphonic acid dimethyl ester;

20 {4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl}-phosphonic acid diethyl ester;

{4-[2-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-phenyl}-phosphonic acid dibutyl ester;

25 {4-[2-(1,1,2,3,3-Pentamethyl-indan-5-yl)-propenyl]-phenyl}-phosphonic acid diethyl ester;

6-(2-Biphenyl-4-yl-1-methyl-vinyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;

6-[2-(2-Fluoro-phenyl)-1-methyl-vinyl]-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;

30 6-[2-(2-Fluoro-phenyl)-1-methyl-vinyl]-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;

6-[2-(4-Chloro-phenyl)-1-methyl-vinyl]-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;

35 6-[2-(2-Bromo-phenyl)-1-methyl-vinyl]-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;

- 63 -

6-[2-(3-Bromo-phenyl)-1-methyl-vinyl]-
1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;
6-[2-(4-Iodo-phenyl)-1-methyl-vinyl]-
1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-naphthalene;
5 1,1,4,4-Tetramethyl-6-[1-methyl-2-(4-nitro-
phenyl)-vinyl]-1,2,3,4-tetrahydro-naphthalene;
1,1,3,3-Tetramethyl-indan-5-carboxylic acid
(4-fluoro-phenyl)-amide;
5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-
10 naphthalene-2-carboxylic acid (4-fluoro-phenyl)-amide;
9,9-Dimethyl-6,7,8,9-tetrahydro-5H-benzocyclo-
heptene-2-carboxylic acid (4-fluoro-phenyl)-amide;
7,7-Dimethyl-6,7,8,9-tetrahydro-5H-benzocyclo-
heptene-2-carboxylic acid (4-fluoro-phenyl)-amide;
15 4-Fluoro-N-(1,1,3,3-tetramethyl-indan-5-yl)-
benzamide;
4-Fluoro-N-(5,5,8,8-tetramethyl-5,6,7,8-tetra-
hydro-naphthalen-2-yl)-benzamide;
N>1_,N>1_-Dimethyl-N>2_-{4-[2-(5,5,8,8-tetra-
20 methyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propenyl]-
phenyl}-ethane-1,2-diamine;
Methyl-(2-morpholin-4-yl-ethyl)-{4-[2-
(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-
2-yl)-propenyl]-phenyl}-amine;
25 6-{2-[4-(2-Methoxy-ethylsulfanyl)-phenyl]-
1-methyl-vinyl}-1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-
naphthalene; and
1,1,4,4-Tetramethyl-6-{1-methyl-2-[4-(2-methyl-
sulfanyl-ethylsulfanyl)-phenyl]-vinyl}-1,2,3,4-tetra-
30 hydro-naphthalene.

As can be seen from the foregoing, this invention
contemplates the use of any compound which falls within
the generic term "retinoids". All that is required to
lower plasma levels of Lp(a) according to this
35 invention is to administer to an animal an Lp(a)
lowering amount of a retinoid. All of the retinoids to

- 64 -

be utilized are either known or are readily prepared as described by Dawson and Hobbs, *ibid.*, which is incorporated herein by reference.

5 We have evaluated several specific retinoids for their ability to lower Lp(a) levels in animals. The compounds were evaluated according to the following protocol.

Hepatocytes were isolated from male monkeys (Cynomolgus macaca) of approximately 6.5 kg as described by Ulrich RG, Aspar DG, Cramer CT, Kletzien RF, Ginsberg LC, In Vitro Cell Dev. Biol. 1990;26:815-23, except that the final cell suspension was purified by Percoll density gradient centrifugation. The resulting cell pellet, containing the viable hepatocytes, was washed, counted, and resuspended in fetal bovine serum (FBS), 90%, and DMSO, 10%, at a concentration of 10^6 cells/mL. Cells were frozen in the FBS/DMSO medium at a rate of 1/minute using a controlled-rate liquid nitrogen freezer and stored in a liquid nitrogen freezer. Only previously frozen cells were used. Frozen cells were thawed in a 37°C water bath, pelleted by centrifugation, resuspended in Dulbecco's modified eagle medium (DMEM) containing FBS, 10%, and plated at a concentration 3×10^6 cells/60-mm plate. The medium was changed 4 hours later. The next day (Day 0) the medium was replaced with fresh medium not containing FBS and a further 24-hour incubation was carried out. All subsequent incubations were performed in the absence of FBS, however, the culture medium was supplemented with 0.2% bovine serum albumin (BSA). On Day 1 fresh medium was added to the cells. The following day (Day 2) drug treatment was initiated by incubating the cells for 24 hours with the test compounds or the appropriate concentration of the DMSO vehicle (0.3%-0.5%).

35 Triplicate wells were used for each retinol or DMSO

-65-

dose. Every 24 hours for the next 2 days (Days 2 and 3) fresh medium containing the test compounds or DMSO was added to the cells. On Day 5 the medium was collected, frozen at -70°C, and within 1 week analyzed for Lp(a) levels using a specific Lp(a) ELISA. The data is presented in Table 1 and is expressed as percent inhibition at a single concentration, relative to cells treated with vehicle only.

10

-66-

TABLE I

	Compound at 10 μ M	Percent Lowering of L_p (a)
	All trans-Retinoic acid	80
5	All trans-Retinoic acid, methyl ester	37
	All trans-Retinal	80
	All trans-Retinol	77
10	9-cis-retinoic acid	42
	13-cis-retinol	59
15	13-cis-retinal	66
	9-cis-retinal	76
20	3-methyl-5-(2,6,6-trimethyl-1-cyclohexan-1-yl)-2,4-pentadienoic acid	34
	3-methyl-5-(2,6,6-trimethyl-1-cyclohexan-1-yl)-2,4-pentadienoic acid, methyl ester	68
25	3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienoic acid, ethyl ester	46
	3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadien-1-ol	50
30	3-methyl-5-(2,6,6-trimethyl)-1-cyclohexen-1-yl)-2,4-pentadienal	72
35	3-methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-pentanoic acid	28
	5,5,6-trimethyl-3-cyclohexen-1-carboxaldehyde	20

40

For use in the method of this invention, the retinoids preferably are combined with one or more pharmaceutically acceptable diluents, carriers, excipients, or the like, for convenient oral, parenteral, and topical administration to animals, preferably humans. The retinoids are ideally suited to formulation for oral administration in the form of tablets, capsules, dispersible powders, granules, suspensions, elixirs, buccal seals, and the like. The

45

-67-

formulations typically will contain from about 1% to about 90% by weight of active retinoid, and more commonly from about 5% to about 60% by weight.

Oral formulations can contain, for suspensions, from about 0.05% to about 5% by weight of a suspending agent, such as talc or the like, and syrups will contain from about 10% to about 50% by weight of a sugar such as dextrose. Tablets may contain normal amounts of binders, stabilizers, and common diluents such as corn starch and sugars. Parenteral formulations, for instance, solutions for IV injection, will be made by dissolving or suspending the retinoid in a solvent such as isotonic saline or 5% glucose in sterile water.

The dose of retinoid to be administered is that amount which is effective for lowering plasma levels of Lp(a) in an animal.

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, and the severity of the condition being treated. However, in general, satisfactory results are obtained when the retinoids are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in sustained-release form. For most large mammals, such as humans, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

-68-

The retinoids may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose, and kaolin, while liquid carriers include sterile water, polyethylene glycols, nonionic surfactants, and edible oils such as corn, peanut, and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT, and BHA.

The preferred pharmaceutical compositions from the stand point of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage

-69-

and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (eg, glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

The compounds may also be encapsulated in liposomes to allow an intravenous administration of the drug. The liposomes suitable for use in the invention are lipid vesicles and may include plurilamellar lipid vesicles, small sonicated multimellar vesicles, reverse phase evaporation vesicles, large multilamellular vesicles, and the like, wherein the lipid vesicles are formed by one or more phospholipids such as phosphatidylcholine, phosphatidylglycerol, sphingomyelin, phospholactic acid, and the like. In addition, the liposomes may also comprise a sterol component such as cholesterol.

Some typical formulations which can be administered to humans are as follows:

Tablet Formulation

4-[2-(3,4-di-n-butylphenyl)-propenyl]-benzoic acid (250 mg) is blended to uniformity with 100 mg of corn starch and 50 mg of lactose. The mixture is compressed into a tablet. Such tablets are administered orally at the rate of one to three times a day.

- 70 -

Preparation of Oral Suspension

	Ingredient	Amount
	4,4-dimethyl-7-(1-methyl-2-phenylvinyl)chroman	500 mg
5	Sorbitol solution (70% NF)	40 mL
	Sodium benzoate	150 mg
	Saccharin	10 mg
10	Red dye	10 mg
	Cherry flavor	50 mg
15	Distilled water qs OD	100 mL

The sorbitol solution is added to 40 mL of distilled water and the retinoid is suspended thereon.

20 The saccharin, sodium benzoate, flavor, and dye are added and dissolved. The volume is adjusted to 100 mL with distilled water. Each milliliter of syrup contains 5 mg of retinoid.

25 Suppositories

A mixture of 400 mg of 4-(2,4-diisopropylbenzoyl)-benzoic acid and 600 mg of theobroma oil is stirred at 60°C to uniformity. The mixture is cooled and allowed

30 to harden in a tapered mold to provide a 1-g suppository.

Parenteral Solution

35 In a solution of 700 mL of propylene glycol and 200 mL of sterile water is suspended 20.0 g of retinoic acid. The pH is adjusted to pH 6.5 with dilute sodium hydroxide, and the volume is made up to 100 mL with water for injection. The formulation is sterilized,

40 filled into 5.0-mL ampoules each containing 2.0 mL

-71-

(representing 40 mg of drug), and sealed under nitrogen.

Preferred formulations are those incorporating any of the preferred retinoids to be utilized to lower
5 Lp(a). Specifically preferred are all trans isomers of retinoic acid, retinal, and retinol. Also preferred are the 9-cis isomers of retinoic acid, retinal, and retinol, as well as the 13-cis isomers of retinoic
10 acid, retinal, and retinol. Certain retinoid esters also are preferred, for example, 3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid, methyl ester.

- 72 -

CLAIMS

1. A method of lowering plasma Lp(a) levels in a mammal comprising administering an Lp(a) lowering amount of a retinoid.
2. A method of Claim 1 employing all trans-retinoic acid.
3. A method of Claim 1 employing 3,7-dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-tetraenoic acid, methyl ester.
4. A method of Claim 1 employing all trans-retinal.
5. A method of Claim 1 employing all trans-retinol.
6. A method of Claim 1 employing 9-cis-retinoic acid.
7. A method of Claim 1 employing 13-cis-retinol.
8. A method of Claim 1 employing 13-cis-retinal.
9. A method of Claim 1 employing 9-cis-retinol.
10. A method of Claim 1 employing 13-cis-retinoic acid.
11. A method of Claim 1 employing 9-cis-retinal.

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 95/16305

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/07 A61K31/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 219 888 (KATOCS JR ET AL.) 15 June 1993 see the whole document ---	1,2,6
X	ARTERIOSCLEROSIS AND THROMBOSIS, vol. 13, no. 10, 1993, pages 1505-1514, XP000568450 A. KAPTEIN ET AL.: "Retinoids stimulate ApoA-I synthesis by induction of gene transcription in primary hepatocyte cultures from cynomolgus monkey." see page 1511 - page 1513 --- -/--	1,2,6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

22 April 1996

Date of mailing of the international search report

06.05.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/16305

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MED. CLIN. NORTH AM., vol. 78, no. 1, 1994, pages 117-141, XP000568976 N.J. STONE: "Secondary causes of hyperlipidemia." see page 126</p>	
A	<p style="text-align: center;">---</p> <p>ARCH. DERMATOL., vol. 119, no. 12, 1983, pages 987-993, XP002001144 L.A. ZECH ET AL.: "Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study." -----</p>	

information on patent family members

PC7/US 95/16305

U.S. GOVERNMENT PRINTING OFFICE: 1969